Trial · NCT02886702

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702, Phase 3, Completed, Fougera Pharmaceuticals Inc.; results first posted 2018-08-29

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis. Trials, record NCT02886702. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02886702

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis
NCT number: NCT02886702
Status: Completed
Phases: Phase 3
Enrollment: 855 participants, actual
Lead sponsor: Fougera Pharmaceuticals Inc.
Conditions: Plaque Psoriasis
Interventions: Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo
First posted: 2016-09-01
Last updated: 2018-08-29
Results first posted: 2018-08-29

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Treatment Success Assessed by IGA	Week 12	Proportion of subjects with treatment success (defined as none, minimal or mild disease, a score of 0, 1 or 2 within the treatment area) on the "Investigator's Global Assessment of Disease Severity" (IGA) at the Week 12 visit (Day 85 ± 4 days, End of Study).
Secondary	Disease Severity None or Minimal on IGA	Week 12	Proportion of subjects with none or minimal disease, a score of 0 or 1 on the IGA at the Week 12 visit (Day 85 ± 4 days, End of Study).
Secondary	Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI	Week 12	Proportion of subjects with target site plaque elevation, scaling and erythema scores of less than or equal to 1 (Clear or Almost Clear) on the Psoriasis Area Severity Index (PASI) at the Week 12 visit (Day 85 ± 4 days, End of Study).

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Treatment Success Assessed by IGA	Week 12	mITT for superiority versus placebo, PP for equivalence versus Reference	Percentage of Participants	NUMBER
SECONDARY	Disease Severity None or Minimal on IGA	Week 12	mITT	Percentage of Participants	NUMBER
SECONDARY	Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI	Week 12	mITT	Percentage of Participants	NUMBER

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Treatment Success Assessed by IGA	Test	60.8	Percentage of Participants
Treatment Success Assessed by IGA	Reference	63.2	Percentage of Participants
Treatment Success Assessed by IGA	Placebo	56.0	Percentage of Participants
Disease Severity None or Minimal on IGA	Test	17.5	Percentage of Participants
Disease Severity None or Minimal on IGA	Reference	22.6	Percentage of Participants
Disease Severity None or Minimal on IGA	Placebo	16.4	Percentage of Participants
Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI	Test	16.3	Percentage of Participants
Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI	Reference	22.2	Percentage of Participants
Target Site Plaque Elevation, Scaling and Erythema Scores of Less Than or Equal to 1 on the PASI	Placebo	16.0	Percentage of Participants

Source ClinicalTrials.gov

Participant flow15

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Test	284
Overall Study	STARTED	Reference	286
Overall Study	STARTED	Placebo	285
Overall Study	Modified Intent-to Treat (mITT)	Test	263
Overall Study	Modified Intent-to Treat (mITT)	Reference	266
Overall Study	Modified Intent-to Treat (mITT)	Placebo	275
Overall Study	Per-Protocol Population (PP)	Test	208
Overall Study	Per-Protocol Population (PP)	Reference	209
Overall Study	Per-Protocol Population (PP)	Placebo	201
Overall Study	COMPLETED	Test	236

1 to 10 of 15Source ClinicalTrials.gov

See all 15 participant flow

Adverse events51

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Application site dryness	General disorders	Test	2	284
other	Application site dryness	General disorders	Reference	4	286
other	Application site dryness	General disorders	Placebo	2	285
other	Application site erosion	General disorders	Test	5	284
other	Application site erosion	General disorders	Reference	4	286
other	Application site erosion	General disorders	Placebo	6	285
other	Application site erythema	General disorders	Test	5	284
other	Application site erythema	General disorders	Reference	5	286
other	Application site erythema	General disorders	Placebo	4	285
other	Application site pain	General disorders	Test	9	284

1 to 10 of 51Source ClinicalTrials.gov

See all 51 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Test	0	284
Total, all-cause mortality	Reference	0	286
Total, all-cause mortality	Placebo	0	285
Total, other adverse events	Test	31	284
Total, other adverse events	Reference	24	286
Total, other adverse events	Placebo	21	285
Total, serious adverse events	Test	0	284
Total, serious adverse events	Reference	0	286
Total, serious adverse events	Placebo	3	285

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02886702

GET https://conductscience.org/api/trials/v1/NCT02886702/events?page=2

API reference For AI assistants